Featured Posts

Wednesday, February 6, 2019

Rewind Therapeutics Expands Scientific Advisory Board with Addition of Professors Robin Franklin and Catherine Lubetzki, Bringing Further Expertise in Myelin and Multiple Sclerosis Research

LEUVEN, Belgium, Feb. 6, 2019 /PRNewswire/ -- Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for myelin-related diseases, today announces the appointment of leading myelin and multiple sclerosis ("MS")...



from PR Newswire: https://prn.to/2MT28Yi

No comments:

Post a Comment